Simona Capponi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Simona Capponi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Emilia Bellone
University of Genova
2 shared publications - Paola Mandich
IRCCS Ospedale Policlinico San Martino Genoa Italy
2 shared publications - Alessandro Geroldi
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, University of Genova, Largo P. Daneo 3, 16132 Genova, Italy
1 shared publication - Angelo Schenone
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences (DINOGMI), University of Genoa, Largo P. Daneo 3, 16132 Genova, Italy
1 shared publication - Bas Castelijns
Hubrecht Institute-KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, Netherlands
1 shared publication Cara Fernandez-Cerado
Sunshine Care Foundation, Roxas City, 5800 Capiz, Philippines
1 shared publication
Latest Publications
- Open Access
- 27 October 2021
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 3 (4) , fcab253
Dissection of TAF1 neuronal splicing and implications for neurodegeneration in X-linked dystonia-parkinsonism
X-linked dystonia-parkinsonism (XDP) is a monogenic neurodegenerative disorder of the basal ganglia, which presents as a combination of hyperkinetic movements and parkinsonian features. The underlying genetic mechanism involves the insertion of a SINE-VNTR-Alu retrotransposon within the TAF1 gene. Interestingly, alterations of TAF1 have been involved in multiple neurological diseases. In XDP, the SINE-VNTR-Alu insertion in TAF1 has been proposed to result in alternative splicing defects, including the decreased incorporation of a neuron-specific microexon annotated as 34′. This mechanism has become controversial as recent studies failed to provide support. In order to resolve this conundrum, we examined the alternative splicing patterns of TAF1 mRNAs in XDP and control brains. The impact of the disease-associated SINE-VNTR-Alu on alternative splicing of microexon 34′ was further investigated in cellular assays. Subsequently, microexon 34′ incorporation was explored by RT-PCR and Nanopore long-read sequencing of TAF1 mRNAs from XDP and control brains tissues. Using cell-based splicing assays, we demonstrate that presence of the disease-associated SINE-VNTR-Alu does not affect the inclusion of microexon 34′. In addition, we show that (1) microexon 34′-containing TAF1 mRNAs are detected at similar levels in XDP as in controls and that (2) the architecture of TAF1 transcripts is remarkably similar between XDP and controls brains. These results indicate that microexon 34′ incorporation into TAF1 mRNA is not affected in XDP brains. Our findings shift the current paradigm of XDP by discounting alternative splicing of TAF1 microexon 34′ as the molecular basis for this disease.
- 27 October 2021
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 3 (4) , fcab253
Open AccessDissection of TAF1 neuronal splicing and implications for neurodegeneration in X-linked dystonia-parkinsonism
X-linked dystonia-parkinsonism (XDP) is a monogenic neurodegenerative disorder of the basal ganglia, which presents as a combination of hyperkinetic movements and parkinsonian features. The underlying genetic mechanism involves the insertion of a SINE-VNTR-Alu retrotransposon within the TAF1 gene. Interestingly, alterations of TAF1 have been involved in multiple neurological diseases. In XDP, the SINE-VNTR-Alu insertion in TAF1 has been proposed to result in alternative splicing defects, including the decreased incorporation of a neuron-specific microexon annotated as 34′. This mechanism has become controversial as recent studies failed to provide support. In order to resolve this conundrum, we examined the alternative splicing patterns of TAF1 mRNAs in XDP and control brains. The impact of the disease-associated SINE-VNTR-Alu on alternative splicing of microexon 34′ was further investigated in cellular assays. Subsequently, microexon 34′ incorporation was explored by RT-PCR and Nanopore long-read sequencing of TAF1 mRNAs from XDP and control brains tissues. Using cell-based splicing assays, we demonstrate that presence of the disease-associated SINE-VNTR-Alu does not affect the inclusion of microexon 34′. In addition, we show that (1) microexon 34′-containing TAF1 mRNAs are detected at similar levels in XDP as in controls and that (2) the architecture of TAF1 transcripts is remarkably similar between XDP and controls brains. These results indicate that microexon 34′ incorporation into TAF1 mRNA is not affected in XDP brains. Our findings shift the current paradigm of XDP by discounting alternative splicing of TAF1 microexon 34′ as the molecular basis for this disease.
- 1 August 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 343 (1-2) , 183-186
A novel LITAF/SIMPLE mutation within a family with a demyelinating form of Charcot–Marie–Tooth disease
- 1 August 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 343 (1-2) , 183-186
A novel LITAF/SIMPLE mutation within a family with a demyelinating form of Charcot–Marie–Tooth disease
- Open Access
- 16 December 2011
- Published by Wiley in Annals of Neurology
- Vol. 71 (3) , 427-431
Gain of glycosylation: A new pathomechanism of myelin protein zero mutations
We report the first case of a missense mutation in MPZ causing a gain of glycosylation in myelin protein zero, the main protein of peripheral nervous system myelin. The patient was affected by a severe demyelinating neuropathy caused by a missense mutation, D32N, that created a new glycosylation sequence. We confirmed that the mutant protein is hyperglycosylated, is partially retained into the Golgi apparatus in vitro, and disrupts intercellular adhesion. By sequential experiments, we demonstrated that hyperglycosylation is the main mechanism of this mutation. Gain of glycosylation is a new mechanism in Charcot–Marie–Tooth type 1B. Ann Neurol 2012;71:–
- 16 December 2011
- Published by Wiley in Annals of Neurology
- Vol. 71 (3) , 427-431
Open AccessGain of glycosylation: A new pathomechanism of myelin protein zero mutations
We report the first case of a missense mutation in MPZ causing a gain of glycosylation in myelin protein zero, the main protein of peripheral nervous system myelin. The patient was affected by a severe demyelinating neuropathy caused by a missense mutation, D32N, that created a new glycosylation sequence. We confirmed that the mutant protein is hyperglycosylated, is partially retained into the Golgi apparatus in vitro, and disrupts intercellular adhesion. By sequential experiments, we demonstrated that hyperglycosylation is the main mechanism of this mutation. Gain of glycosylation is a new mechanism in Charcot–Marie–Tooth type 1B. Ann Neurol 2012;71:–